Please provide your email address to receive an email when new articles are posted on . Marked type 2 inflammation was present in eosinophilic cellulitis lesions. Preferential activation of the Janus ...

In China, the real-world effectiveness and safety of Janus kinase 1 (JAK1) inhibitors for moderate-to-severe atopic dermatitis (AD) are of significant interest due to the approval of upadacitinib and ...

Ivarmacitinib, a novel Janus kinase 1 inhibitor, alleviates symptoms, reduces disease activity, and improves physical function and quality of life in patients with moderate to severe rheumatoid ...

Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ...

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

Ivarmacitinib, a highly selective Janus kinase 1 (JAK1) inhibitor, tamed ankylosing spondylitis with sustained efficacy through 24 weeks in a phase 2/3 trial. A phase 2/3 trial in China evaluated the ...